DOCKET NO.: ORT-1482 US **PATENT**
Application No.: 09/922,874
Office Action Dated: November 19, 2003

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the formula



or a pharmaceutically acceptable salt thereof, wherein

(a) R_9 is selected from the group consisting of H, thienyl, furanyl, pyrrolyl, phenyl, substituted phenyl, pyridinyl, substituted pyridinyl, naphthyl, benzo[b]thien-2-yl, 2-benzofuranyl, pyrimidine and 2,4-(bismethoxyphenyl)-5-pyrimidinyl,

said substituted phenyl having the formula



wherein (i) R_{12} is H, OH, lower alkylthio, alkoxy, alkylamine, dialkylamine, halogen-substituted lower alkyl, halogen substituted lower alkoxy, cyano, cyanoalkyl, phenyl, phenylalkoxy or substituted piperazinyl, N-(t-butoxy)carbamylalkyl, (ii) each R_{13} is independently H, NO_2, alkoxy, alkylamino, dialkylamino, halogen-substituted lower alkyl, halogen-substituted lower alkoxy or phenyl, and (iii) each R_{14} is independently H, alkoxy, phenyloxy or phenylalkoxy;

PAGE 3/12 * RCVD AT 5/19/2004 6:04:39 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID: * DURATION (mm-ss):03-16

(b) R_{10} is selected from the group consisting of cyanoalkyl, alkylamino, dialkylamino, hydroxy-substituted alkylamino and hydroxy-substituted dialkylamino; and

(c) R_{11} is H or lower alkyl.

2. (Original) The pharmaceutical composition of claim 1, wherein R_9 is substituted phenyl.

3. (Original) The pharmaceutical composition of claim 1, wherein R_{11} is H and R_{10} is dialkylamino or hydroxy-substituted dialkylamino.

4. (Original) The pharmaceutical composition of claim 1, wherein the compound is N1,N1-dimethyl-N4-[6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]-1,4-benzenediamine.

5. (Original) The pharmaceutical composition of claim 1, wherein the compound is N1-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N4,N4-dimethyl-1,4-benzenediamine.

6. (Original) The pharmaceutical composition of claim 1, wherein the compound is N1-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]-N4,N4-dimethyl-1,4-benzenediamine.

7. (Original) The pharmaceutical composition of claim 1, wherein the compound is 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]-ethanol.

8. (Original) The pharmaceutical composition of claim 1, wherein the compound is 2-[[4-[(6-benzo[b]thien-2-yl-4-pyrimidinyl)amino]phenyl]ethylamino]-ethanol.

9. (Original) The pharmaceutical composition of claim 1, wherein the compound is 2-[ethyl[4-[[6-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenyl] amino]-ethanol.

PAGE 4/12 * RCVD AT 5/19/2004 6:04:39 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID: * DURATION (mm-ss):03-16

10. (Original) The pharmaceutical composition of claim 1, wherein the compound is of the formula



11. Previously canceled.

12. (Currently Amended) A method for reducing ischemic death in a cell population containing at least one cell type that has been identified as being protected from ischemic death in the presence of the pharmaceutical composition of claim 1, the method comprising the steps of contacting the cell population containing the at least one cell type identified as being protected from ischemic death in the presence of the pharmaceutical composition of claim 1 with an amount of the ~~compound~~ pharmaceutical composition of claim 1 effective to reduce the ischemic death in the cell population.

13. Previously canceled.

14. (Currently Amended) The method of claim 12, wherein the cell population is heterogeneous and comprises a cell selected from the group consisting of a neuronal cell, a glial cell, a cardiac cell, a lymphocyte, a macrophage and a fibroblast.

15. Previously canceled.

16. (Currently Amended) A method of reducing death in response to a traumatic event in a cell population containing at least one cell type that has been identified as being protected from ischemic death in the presence of the pharmaceutical composition of claim 1, and further containing ~~comprising~~ neuronal cells, ~~in response to a traumatic event~~ the method comprising contacting the neuronal cells with the compound contained in the pharmaceutical composition of claim 1 prior to, during, or within a suitable time period following the traumatic event, wherein the neuronal cells are contacted with an amount of the compound effective to reduce the death in the cell population.

17. Previously canceled.

18. (Original) The method of claim 12 wherein the contacting is performed *in vitro*.

19. (Original) The method of claim 14, wherein the contacting is performed *in vitro*.

20. (Original) The method of claim 12 , wherein the contacting is performed *ex vivo*.

21. (Original) The method of claim 14, wherein the contacting is performed *ex vivo*.

22. (Original) The method of claim 12 , wherein the contacting is performed *in vivo*.

23. (Original) The method of claim 14, wherein the contacting is performed *in vivo*.

24. (Currently Amended) A method of reducing ~~neuronal~~ cell death in response to a traumatic event in a subject, comprising administering to the subject a the pharmaceutical composition of claim 1 prior to, during, or following the traumatic event, wherein the subject is administered an amount of the compound effective to reduce the ~~neuronal~~ cell

PAGE 6/12 * RCVD AT 5/19/2004 6:04:39 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID: * DURATION (mm-ss):03-16

death of at least one cell type that has been identified as being protected from ischemic death in the presence of the pharmaceutical composition of claim 1.

25. Previously canceled.

26. (Original) The method of claim 24, wherein the subject is a human.

27. (Original) The method of claim 24, wherein the traumatic event is selected from the group consisting of a medical disorder, a physical trauma, a chemical trauma and a biological trauma.

28. (Original) The method of claim 24, wherein the pharmaceutical composition is administered prior to the traumatic event.

29. (Original) The method of claim 24, wherein the pharmaceutical composition is administered during the traumatic event.

30. (Original) The method of claim 24, wherein the pharmaceutical composition is administered subsequent to the traumatic event.

31–66. Previously canceled.

PAGE 7/12 * RCVD AT 5/19/2004 6:04:39 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID: * DURATION (mm-ss):03-16